一个泛癌症分析确定SOAT1作为一个免疫和预后生物标志物
Yangqing Huang1,2, Xinlan Zhou1, Xiufen Li1
1Department of Hepatobiliary Medicine, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Oncology research
|June 12, 2023
概括
醇o-转移酶1 (SOAT1) 在大多数癌症中是升高的,并预测患者的预后. SOAT1表达与免疫细胞透相关,可能是癌症免疫治疗的目标.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 固醇o-乙转移酶1 (SOAT1) 调节脂质代谢. 固醇o-乙转移酶1 (SOAT1) 调节脂质代谢. 固醇o-乙转移酶1 (SOAT1) 调节脂质代谢. 固醇o-乙转移酶1 (SOAT1) 调节脂肪代谢.
- SOAT1在癌症免疫反应中的作用尚不清楚.
- 了解SOAT1的功能对于癌症研究至关重要.
研究的目的:
- 调查SOAT1在胰腺癌中的预测价值.
- 探索SOAT1在各种癌症类型中的生物功能.
- 评估SOAT1与免疫反应和预后的关联.
主要方法:
- 从TCGA和GTEx数据库获取了33种癌症类型的SOAT1表达数据.
- 通过使用组织微阵列评估蛋白质水平,验证了SOAT1基因表达.
- 进行了共同表达分析和基因组丰富分析 (GSEA).
主要成果:
- 在大多数癌症中,SOAT1表达显著增加,与预后较差相关.
- 升高的SOAT1水平与T细胞,中性粒细胞和巨细胞透的增加有关.
- SOAT1联合表达分析揭示了与免疫基因,适应性免疫和细胞因子信号传递的联系.
结论:
- 在各种癌症中,SOAT1被上调,并作为预后生物标志物.
- SOAT1的表达与免疫细胞透和瘤微环境有关.
- SOAT1代表了增强瘤免疫疗法的潜在治疗标.
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
02:21Cancers Originate from Somatic Mutations in a Single Cell
12.1K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.1K